%PDF-1.4
%
96 0 obj
<>
endobj
93 0 obj
<>
endobj
186 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-11-12T10:22:40Z
2024-03-28T16:09:49-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T16:09:49-07:00
application/pdf
Heather
2004-205.dec
uuid:f02d553f-1dd1-11b2-0a00-a90827bd3700
uuid:f02d5542-1dd1-11b2-0a00-5b0000000000
endstream
endobj
80 0 obj
<>
endobj
82 0 obj
<>
endobj
81 0 obj
<>
endobj
83 0 obj
<>
endobj
48 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 74 0 R/Type/Page>>
endobj
187 0 obj
[192 0 R]
endobj
188 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.85091 0.85091 0.85091 rg
/T1_0 19 Tf
0.6229 0.7822 -0.7822 0.6229 12.739 54.1879 Tm
(Personal non-commercial use only. The Journal of Rheumatology. Copyright\
\251 2004. All rights reserved)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
12 789 587 -785 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
53.46 77 m
558.47 77 l
S
0 0 0 0 k
52.32 70.16 64.18 -15.66 re
f*
BT
0 0 0 1 k
/T1_1 1 Tf
8 0 0 8 53.3216 57.2343 Tm
(2346)Tj
-0.00011 Tc 0.02499 Tw 45.8175 -0.125 Td
(The Journal of Rheumatology 2004; 31:12)Tj
/T1_2 1 Tf
-44.9867 85.1619 Td
[(8.)-875.1 (Bathon JM, Martin R)54.8 (W)91.8 (, Fleischmann RM, et al. )54.8 (A)-220.1 (comparison of)]TJ
1.675 -1.25 Td
(etanercept and methotrexate in patients with early rheumatoid)Tj
0 -1.25 TD
(arthritis. N Engl J Med 2000;343:1586-93.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (Y)99.8 (okata S, Miyamae )17.7 (T)74 (, Imagawa )17.7 (T)74 (, et al. Phase II trial of anti-IL6)]TJ
1.675 -1.25 Td
(receptor antibody \(MRA\) for children with systemic onset juvenile)Tj
T*
[(idiopathic arthritis [abstract]. )54.8 (Arthritis Rheum 2003;48 Suppl:S429.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (Maini RN, )17.7 (T)69.9 (aylor PC, Pavelk K, et al. Ef)17.7 (ficacy of IL6 receptor)]TJ
2.175 -1.25 Td
(antagonist Mra in rheumatoid arthritis patients with an incomplete)Tj
T*
[(response to methotrexate \(CHARISMA\) [abstract]. )54.8 (Arthritis Rheum)]TJ
0 Tc T*
(2003;48 Suppl:S652.)Tj
-0.00011 Tc -2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Firestein GS, Zvaifler NJ. How important are )17.7 (T)-257.1 (cells in chronic)]TJ
2.1381 -1.25 Td
[(rheumatoid synovitis?: II. )17.7 (T)-257.1 (cell-independent mechanisms from)]TJ
T*
[(beginning to end. )54.8 (Arthritis Rheum 2002;46:298-308.)]TJ
-2.175 -1.25 Td
[(12.)-875.1 (Miossec P)110.7 (, van den Ber)17.7 (g )17.7 (W)91.9 (.)-0.1 ( )17.7 (TH1/TH2 cytokine balance in arthritis.)]TJ
2.175 -1.25 Td
(Arthritis Rheum 1997;40:2105-15.)Tj
-2.175 -1.25 Td
[(13.)-875.1 (Firestein GS. Evolving concepts of rheumatoid arthritis. Nature)]TJ
0 Tc 0 Tw 2.175 -1.25 Td
(2003;423:356-61.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(14.)-875.1 (Hitchon CA, El Gabalawy HS. Immune features of seronegative)]TJ
2.175 -1.25 Td
(and seropositive arthritis in early synovitis studies. Curr Opin)Tj
T*
(Rheumatol 2002;14:348-53.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )54.8 (American Rheumatism)]TJ
2.175 -1.25 Td
(Association 1987 revised criteria for the classification of )Tj
T*
[(rheumatoid arthritis. )54.8 (Arthritis Rheum 1988;31:315-24.)]TJ
-2.175 -1.25 Td
[(16.)-875.1 (Dougados M, van der Linden S, Juhlin R, et al. )17.7 (The European)]TJ
2.175 -1.25 Td
(Spondylarthropathy Study Group preliminary criteria for the )Tj
T*
[(classification of spondylarthropathy)64.9 (. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1991;34:1218-27.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(17.)-875.1 (Sokal R, Michener CD. )54.8 (A)-220.1 (statistical method for evaluating )]TJ
2.175 -1.25 Td
(systematic relationships. Univ Kansas Sci Bull 1958;38:1409-38.)Tj
-2.175 -1.25 Td
[(18.)-875.1 (Qin S, Rottman JB, Myers P)110.7 (, et al. )17.7 (The chemokine receptors)]TJ
2.175 -1.25 Td
[(CXCR3 and CCR5 mark subsets of )17.7 (T)-257.1 (cells associated with certain)]TJ
T*
(inflammatory reactions. J Clin Invest 1998;101:746-54.)Tj
-2.175 -1.25 Td
[(19.)-875.1 (Ruth JH, Rottman JB, Katschke KJ Jr)39.7 (, et al. Selective lymphocyte)]TJ
2.175 -1.25 Td
[(chemokine receptor expression in the rheumatoid joint. )54.8 (Arthritis)]TJ
0 Tc T*
(Rheum 2001;44:2750-60.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(20.)-875.1 (Shahrara S, )54.8 (Amin MA, )17.7 (W)79.9 (oods JM, Haines GK, Koch )54.8 (AE.)]TJ
2.175 -1.25 Td
(Chemokine receptor expression and in vivo signaling pathways in)Tj
T*
[(the joints of rats with adjuvant-induced arthritis. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2003;48:3568-83.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(21.)-875.1 (Bosco MC, Puppo M, Pastorino S, et al. Hypoxia selectively)]TJ
2.175 -1.25 Td
(inhibits monocyte chemoattractant protein-1 production by)Tj
T*
(macrophages. J Immunol 2004;172:1681-90.)Tj
-2.175 -1.25 Td
[(22.)-875.1 (V)59.8 (roon )54.8 (A, Heijnen CJ, Lombardi MS, et al. Reduced GRK2 level in)]TJ
2.175 -1.25 Td
[(T)-257.1 (cells potentiates chemotaxis and signaling in response to CCL4. )]TJ
T*
(J Leukoc Biol 2004;75:901-9.)Tj
-2.175 -1.25 Td
[(23.)-875.1 (Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22)]TJ
2.175 -1.25 Td
(patients with rheumatoid arthritis treated with B lymphocyte )Tj
0 Tc T*
[(depletion. )54.9 (Ann Rheum Dis 2002;61:883-8.)]TJ
-0.00011 Tc -2.175 -1.25 Td
[(24.)-875.1 (Hill JA, Southwood S, Sette )54.8 (A, Jevnikar )54.8 (AM, Bell DA, Cairns E.)]TJ
2.175 -1.25 Td
[(Cutting edge: the conversion of ar)17.7 (ginine to citrulline allows for a)]TJ
T*
[(high-af)17.7 (finity peptide interaction with the rheumatoid )]TJ
T*
(arthritis-associated HLA-DRB1*0401 MHC class II molecule. )Tj
T*
(J Immunol 2003;171:538-41.)Tj
30.825 65 Td
[(25.)-875.1 (Hornell )17.7 (TM, Beresford GW)91.7 (, Bushey )54.8 (A, Boss JM, Mellins ED.)]TJ
2.175 -1.25 Td
(Regulation of the class II MHC pathway in primary human )Tj
T*
[(monocytes by granulocyte-macrophage colony-stimulating factor)54.8 (. )]TJ
T*
(J Immunol 2003;171:2374-83.)Tj
-2.175 -1.25 Td
[(26.)-875.1 (Alvaro-Gracia JM, Zvaifler NJ, Firestein GS. Cytokines in chronic)]TJ
2.175 -1.25 Td
[(inflammatory arthritis. IV)128.8 (. Granulocyte/macrophage )]TJ
T*
[(colony-stimulating factor)19.7 (-mediated induction of class II MHC )]TJ
T*
(antigen on human monocytes: a possible role in rheumatoid )Tj
T*
(arthritis. J Exp Med 1989;170:865-75.)Tj
0 Tc -2.175 -1.25 Td
[(27.)-875 (Klimiuk P)91.8 (A)0.1 (, Goronzy JJ, Bjorn J, Beckenbaugh RD, )17.7 (W)80 (eyand CM.)]TJ
-0.00011 Tc 2.175 -1.25 Td
[(T)35 (issue cytokine patterns distinguish variants of rheumatoid )]TJ
T*
[(synovitis. )54.8 (Am J Pathol 1997;151:131)36.8 (1-9.)]TJ
-2.175 -1.25 Td
[(28.)-875.1 (Klimiuk P)91.7 (A, Sierakowski S, Latosiewicz R, Cylwik B, Skowronski)]TJ
2.175 -1.25 Td
[(J, Chwiecko J. Serum cytokines in dif)17.7 (ferent histological variants of)]TJ
T*
[(rheumatoid arthritis. J Rheumatol 2001;28:121)36.8 (1-7.)]TJ
-2.175 -1.25 Td
[(29.)-875.1 (El Gabalawy H, Hitchon C, Schumacher HR, )36.8 (Y)99.8 (arboro C, Duray P)110.7 (,)]TJ
2.175 -1.25 Td
(Goldbach-Mansky R. Synovial histopathological features and RA)Tj
T*
(autoantibodies predict persistence in patients with synovitis of)Tj
T*
[(recent onset [abstract]. )54.8 (Arthritis Rheum 2003;Suppl 48:S667.)]TJ
-2.175 -1.25 Td
[(30.)-875.1 (Alex P)110.7 (,)-0.1 ( )17.7 (W)79.9 (allis G, Szodoray P)110.7 (, et al. )54.8 (A)-220.1 (powerful prognostic tool to)]TJ
2.175 -1.25 Td
(predict treatment outcome in rheumatoid arthritis [abstract].)Tj
T*
(Arthritis Rheum 2003;Suppl 48:S129.)Tj
-2.175 -1.25 Td
[(31.)-875.1 (Shaikh S, Goldbach-Mansky R, El Gabalawy H, Peschken CA.)]TJ
2.175 -1.25 Td
[(Persistent undif)17.7 (ferentiated inflammatory arthritis: longterm )]TJ
T*
[(outcome [abstract]. )54.8 (Arthritis Rheum 2001;44 Suppl:S383. )]TJ
-2.175 -1.25 Td
[(32.)-875.1 (Fong KY)128.8 (, Boey ML, Koh )17.7 (WH, Feng PH. Cytokine concentrations)]TJ
2.175 -1.25 Td
(in the synovial fluid and plasma of rheumatoid arthritis patients:)Tj
T*
(correlation with bony erosions. Clin Exp Rheumatol 1994;12:55-8.)Tj
-2.175 -1.25 Td
[(33.)-875.1 (Kutukculer N, Caglayan S, )54.8 (A)91.8 (ydogdu F)79.7 (. Study of pro-inflammatory)]TJ
2.175 -1.25 Td
[(\(TNF-alpha, IL-1 alpha, IL-6\) and )17.7 (T)91.9 (-cell-derived \(IL-2, IL-4\))]TJ
T*
(cytokines in plasma and synovial fluid of patients with juvenile)Tj
T*
(chronic arthritis: correlations with clinical and laboratory )Tj
T*
(parameters. Clin Rheumatol 1998;17:288-92.)Tj
-2.175 -1.25 Td
[(34.)-875.1 (Okamoto H, )36.8 (Y)99.8 (amamura M, Morita )36.8 (Y)128.9 (, Harada S, Makino H, Ota Z.)]TJ
2.175 -1.25 Td
(The synovial expression and serum levels of interleukin-6, )Tj
T*
[(interleukin-1)36.8 (1, leukemia inhibitory factor)39.7 (, and oncostatin M in)]TJ
T*
[(rheumatoid arthritis. )54.8 (Arthritis Rheum 1997;40:1096-105.)]TJ
-2.175 -1.25 Td
[(35.)-875.1 (Koch )54.8 (AE, Kunkel SL, Harlow LA, et al. Enhanced production of)]TJ
2.175 -1.25 Td
(monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin)Tj
T*
(Invest 1992;90:772-9.)Tj
-2.175 -1.25 Td
[(36.)-875.1 (Klimiuk P)91.7 (A, Sierakowski S, Latosiewicz R, et al. Circulating)]TJ
2.175 -1.25 Td
(tumour necrosis factor alpha and soluble tumour necrosis factor)Tj
T*
[(receptors in patients with dif)17.7 (ferent patterns of rheumatoid synovitis.)]TJ
0 Tc T*
(Ann Rheum Dis 2003;62:472-5.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(37.)-875.1 (Y)99.8 (oussef PP)110.8 (, Haynes DR, )17.7 (T)35 (riantafillou S, et al. Ef)17.7 (fects of pulse)]TJ
2.175 -1.25 Td
(methylprednisolone on inflammatory mediators in peripheral blood,)Tj
T*
(synovial fluid, and synovial membrane in rheumatoid arthritis.)Tj
T*
(Arthritis Rheum 1997;40:1400-8.)Tj
-2.175 -1.25 Td
[(38.)-875.1 (T)69.9 (aylor PC, Peters )54.8 (AM, Paleolog E, et al. Reduction of chemokine)]TJ
2.175 -1.25 Td
[(levels and leukocyte traf)17.7 (fic to joints by tumor necrosis factor alpha)]TJ
T*
[(blockade in patients with rheumatoid arthritis. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2000;43:38-47.)Tj
ET
0 0 0 0 k
/GS0 gs
104.13 81.08 407.5 -10.83 re
f*
0.5 w
104.13 81.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_3 8 Tf
112.368 73 Td
(Personal, non-commercial use only. The Journal of Rheumatology. Copyri\
ght \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
74 0 obj
<>stream
8;Z\6>Af*J%.sKOkj)2O1(OU'[dE4T`N$?PN$%*MKZqL9O@@14n1TjGna(59*)@dK
(WZJ$S=\p53j+]bg^cm1j5S.(&apr&CrbkcFqmWldf=2.6PuatVkT?QYr41I
EdJFgRDe\r@P-dV"=*npb,>!"*4tf:.uO>FM,SQ+<=='/ERPN#.h$P+d.,2);W;,6
9q0pVZ+AB,KN2`19?qk3eijmRHSW4%F.m.Z+(;D3@MCX<8Jb'GegT
\!a%]29i)jp^&!F74Y8O%1;OOI&;bkA]LZU4BREm<4E^lnSb/Xm\@rX@:(!h+0i%1
)\P$+h$N+;f;,NifjYmfYdMnp(Pn[a=M$BXQ!dUX2hiaseWCbi"OYBWB?fMCrrRb-
CB&Y;QT:po;P_ieA')]A259RL@/[Z#%3?6F5
_/&spXA4!noZIbf^/]n2N;VZDg$P:ck8;FQHKTK!+OrfMNlV%>iJY/S2hc;M!j7I+
`if"10a''ZDmV[E\,LV/RjW?%/+o@B+uME\*dKh&GR-I,egc'[m$RhZqfCeUp#!(raQ'!W^_gpIH5
SEXTODdrKO,@/0*Z-qJES>AP7p=Nl9r@
endstream
endobj
78 0 obj
[/Indexed/DeviceRGB 255 77 0 R]
endobj
77 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
163 0 obj
<>
endobj
103 0 obj
<>
endobj
108 0 obj
<>
endobj
140 0 obj
<>
endobj
191 0 obj
<>
endobj
109 0 obj
<>
endobj
132 0 obj
<>stream
H|TPWaFT(v
YIЀ 8(0! |?(hDW@A@fkF6ljwv+o}}{1s3qe}Vb봱
'pn9-KsNji<ԟH%'_R upצwWl1DžGʪ[縹y,Uۣd3#eK/5f%2HVd}2V/[e[cx^?L)d He">F&[huJ
B9W/S8}V*RW)b19Q&$0+1-Űe
ôfXaX1,#0K=(hf0;mvaFn
r|FP#%)\JewVM8maabta쵚aahzuIAd4ܷ
hx4Y4OR:~mj=E2eהΩS}}f9'|puux?6"uH&1O0]Єs .T0?\:LbfSẕ3jbH$FjjS?ba-4P"NgH.7^q3+pw
0{WWW "̫t^#䫑lW 蒶twIĶxOQ[b}&I+?*u;UD~dg7